SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

MBX Biosciences, Inc.
Date: Sept. 22, 2025 · CIK: 0001776111 · Accession: 0001193125-25-211387

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290447

Date
September 22, 2025
Author
P. Kent Hawryluk
Form
CORRESP
Company
MBX Biosciences, Inc.

Letter

VIA EDGAR September 22, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Acceleration Request for Registration Statement on Form S-1 File No. 333-290447

Re: MBX Biosciences, Inc.

Dear Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), MBX Biosciences, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to September 24, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin M. O’Connor at (212) 813-8853. If you have any questions regarding this request, please contact Edwin M. O’Connor of Goodwin Procter LLP at (212) 813-8853.

Sincerely,
MBX BIOSCIENCES, INC.

Show Raw Text
CORRESP
 1
 filename1.htm

 CORRESP

 VIA EDGAR September 22, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549   Attention: Tyler Howes

 Re:
 MBX Biosciences, Inc.

 Acceleration Request for Registration Statement on Form S-1

 File No. 333-290447

 Dear Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), MBX Biosciences, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to September 24, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin M. O’Connor at (212) 813-8853. If you have any questions regarding this request, please contact Edwin M. O’Connor of Goodwin Procter LLP at (212) 813-8853.

 Sincerely,

 MBX BIOSCIENCES, INC.

   /s/ P. Kent Hawryluk P. Kent Hawryluk

 Chief Executive Officer

 cc:
 Richard Bartram, MBX Biosciences, Inc.

 Mitchell S. Bloom, Esq., Goodwin Procter LLP

 Edwin M. O’Connor, Esq., Goodwin Procter LLP